CA Stock MarketDetailed Quotes

BIOV BioVaxys Technology Corp

Watchlist
  • 0.055
  • -0.005-8.33%
15min DelayMarket Closed Jan 13 15:59 ET
14.41MMarket Cap-1.83P/E (TTM)

About BioVaxys Technology Corp Company

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Company Profile

SymbolBIOV
Company NameBioVaxys Technology Corp
Founded2018
MarketCNQ
Employees6
Fiscal Year Ends10-31
Address146 Thirtieth Street Suite 100
CityEtobicoke
CountryCAN
Zip CodeM8W 3D4
Phone+1 646 452-7054

Company Executives

  • Name
  • Position
  • Salary
  • James Passin
  • Chief Executive Officer and Director
  • --
  • David Wang
  • Director
  • --
Trending CA Stocks
Dividend Kings of Canada Dividend Kings of Canada

Dividend Kings In Canada are companies that have increased their Dividend per share for the most consecutive years, reflecting a strong business model and robust financials, and are likely to outperform the market with less volatility. Dividend Kings In Canada are companies that have increased their Dividend per share for the most consecutive years, reflecting a strong business model and robust financials, and are likely to outperform the market with less volatility.